|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007202,
umls-concept:C0008976,
umls-concept:C0017082,
umls-concept:C0205210,
umls-concept:C0205494,
umls-concept:C0242912,
umls-concept:C0392747,
umls-concept:C0524727,
umls-concept:C0679199,
umls-concept:C0814225,
umls-concept:C1274040
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1996-6-14
|
|
pubmed:abstractText |
Many neuroprotective agents (NPAs) are effective in acute experimental cerebral ischemia in animals. None have proven effective in human stroke trials. Even short treatment delays cause substantial efficacy loss. Cardiac surgery under cardiopulmonary bypass (CS-CPB) causes cerebral ischemia with cognitive impairment at a predeterminable time point and should permit efficient screening of NPAs for stroke benefit. We sought to develop sensitive methods to assess dysfunction from CS-CPB in a double-blind trial of the NPA GM1 ganglioside.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0039-2499
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
858-74
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8623106-Adult,
pubmed-meshheading:8623106-Aged,
pubmed-meshheading:8623106-Aged, 80 and over,
pubmed-meshheading:8623106-Brain Ischemia,
pubmed-meshheading:8623106-Cardiopulmonary Bypass,
pubmed-meshheading:8623106-Cognition,
pubmed-meshheading:8623106-Cognition Disorders,
pubmed-meshheading:8623106-Coronary Artery Bypass,
pubmed-meshheading:8623106-Coronary Disease,
pubmed-meshheading:8623106-Double-Blind Method,
pubmed-meshheading:8623106-Female,
pubmed-meshheading:8623106-Follow-Up Studies,
pubmed-meshheading:8623106-G(M1) Ganglioside,
pubmed-meshheading:8623106-Heart Valve Prosthesis,
pubmed-meshheading:8623106-Humans,
pubmed-meshheading:8623106-Male,
pubmed-meshheading:8623106-Middle Aged,
pubmed-meshheading:8623106-Neuroprotective Agents,
pubmed-meshheading:8623106-Neuropsychological Tests,
pubmed-meshheading:8623106-Placebos,
pubmed-meshheading:8623106-Postoperative Complications,
pubmed-meshheading:8623106-Probability,
pubmed-meshheading:8623106-Sensitivity and Specificity,
pubmed-meshheading:8623106-Time Factors
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Evaluating neuroprotective agents for clinical anti-ischemic benefit using neurological and neuropsychological changes after cardiac surgery under cardiopulmonary bypass. Methodological strategies and results of a double-blind, placebo-controlled trial of GM1 ganglioside.
|
|
pubmed:affiliation |
Department of Neurology, New York University Medical Center, NY 10016, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
